Report: Federal 340B Program Needs More Audits, Transparency

Not one audit of a pharmaceutical manufacturer has been conducted as part of the government-run discount drug program 340B, an industry stakeholder complained July 9, saying the program saves taxpayers money but should be more transparent.
Washington Drug Letter